Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)

NCT02616640 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02616640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02616640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
January 11, 2016
Completion date
July 30, 2024
Enrollment
114 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma